MyMD Pharmaceuticals Inc (MYMD)

[leifsmith]

What's essentail to understand about MYMD-1

From today's announcement:

MYMD-1, an oral selective inhibitor of tumor necrosis factor-alpha (TNF-a), a driver of chronic inflammation, is being studied to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan. MYMD-1 has shown effectiveness in pre-clinical and clinical studies in regulating the immune system. Unlike other therapies, MYMD-1 has been shown in these studies to selectively block TNF-a when it becomes overactivated in autoimmune diseases and cytokine storms, but not block it from doing its normal job of being a first responder to any routine type of moderate infection.

MYMD-1’s ease of oral dosing is another differentiator compared to currently available TNF-a blockers, all of which require delivery by injection or infusion.

This is more important than is readily inferred from the price history.

###